More Rhythm Biosciences Limited news
Rhythm Biosciences LimitedASX: RHY

Rhythm Completes Strongly Oversubscribed $4.3M Rights Issue

Sep 7, 2021 at 1:52 AM EDT · Issued by Rhythm Biosciences Limited

Filed with ASX · Sep 7, 2021 at 1:52 AM EDT

On 6ix: 6ix.com/news/rhythm-completes-strongly-oversubscribed-dollar4.3m-rights-issue

Rhythm Biosciences Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Rhythm Biosciences Limited on 6ix

Story so far

  • Rights Issue Investor PresentationJul 30, 2021
  • Non renouneable rights issue prospectusJul 30, 2021
  • Non-renounceable rights issue OfferJul 31, 2020

Earlier from Rhythm Biosciences

  • Initial TGA Regulatory Documentation SubmittedAug 18, 2021
  • Non Renounceable pro rata offer - Completion of despatchAug 9, 2021
  • Rights Issue Investor PresentationJul 30, 2021
  • Non renouneable rights issue prospectusJul 29, 2021
  • Rhythm Establishes US Entity To Drive US Expansion StrategyJul 14, 2021

Later from Rhythm Biosciences

  • TGA Accepts Initial Regulatory DocumentationSep 14, 2021
  • Rhythm Completes Recruitment for Clinical Trial (Study 7)Sep 21, 2021
  • Rhythm Receives $2.4m R&D Tax IncentiveOct 4, 2021
  • ColoSTAT Test Kits Deliver Consistent, High Accuracy ResultsOct 20, 2021
  • RHY - Institutional Investor PresentationNov 9, 2021
All Rhythm Biosciences news releases↗

Follow Rhythm Biosciences into a list and get an email when it puts out news.

Follow Rhythm Biosciences
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer